All In Biotech

Investigational drug · Phase 2

Palacaparib

Also called: AZD9574

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Prostate Cancer, Ovarian Cancer, Endometrial Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

5

5 still active

All registered trials

2

Any phase or sponsor naming "Palacaparib"

First trial start

2021

Oct 18, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Palacaparib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Metastatic Prostate Cancer
  • Ovarian Cancer
  • Endometrial Cancer
  • Breast Cancer
  • Biliary Tract Carcinoma
  • Squamous Non-Small Cell Lung Cancer
  • Lung Adenocarcinoma
  • Lung Squamous Cell Carcinoma
  • Advanced Solid Malignancies

Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Ovarian cancer · Endometrial cancer · Oncology · Kidney and urology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Palacaparib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 14 on PubMed

Also in development for Metastatic Prostate Cancer

  • FPI-2265AZD2265, 225Ac-PSMA-I&TPhase 24 trials

    Fusion Pharmaceuticals Inc. · Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration Resistant Prostate Cancer

  • BalstilimabAGEN2034Phase 23 trials

    ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer

  • AZD2287Imaging agentPhase 22 trials

    AstraZeneca · Metastatic Prostate Cancer

  • ZalifrelimabPhase 22 trials

    ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer

  • AZD0516Phase 21 trial

    AstraZeneca · Metastatic Prostate Cancer

  • AZD0754Phase 21 trial

    AstraZeneca · Metastatic Prostate Cancer

  • AZD8359Phase 21 trial

    AstraZeneca · Metastatic Prostate Cancer

  • GDC-1261Phase 21 trial

    Roche (Genentech) · Advanced Prostate Cancer, Metastatic Prostate Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.